stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) Revenue growth
AbCellera Biologics Inc.'s revenue growth over the twelve months to 30 June 2026 was 101.3%, down 59.3 percentage points from fiscal 2025 (160.6%). Over the past ten years it has ranged from −92.2% (fiscal 2023) to 1,907.9% (fiscal 2020); the current reading is higher than 88% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 160.6% | 184.73 |
| FY2024 | −24.2% | 68.00 |
| FY2023 | −92.2% | (121.55) |
| FY2022 | 29.4% | (31.54) |
| FY2021 | 60.9% | (1,846.96) |
| FY2020 | 1,907.9% | 1,876.39 |
| FY2019 | 31.5% | 55.44 |
| FY2018 | −24.0% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | −76.3% | (172.63) |
| Mar 2026 | 96.3% | (692.03) |
| Dec 2025 | 788.4% | 750.75 |
| Sep 2025 | 37.6% | (95.67) |
| 21 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| ABCL AbCellera Biologics Inc. | 101.3% |
| ARQT Arcutis Biotherapeutics, Inc. compare | 60.0% |
| IOVA Iovance Biotherapeutics, Inc. compare | 51.3% |
| TNGX Tango Therapeutics, Inc. compare | 48.3% |
| ACAD ACADIA Pharmaceuticals Inc. compare | 14.8% |
| XENE Xenon Pharmaceuticals Inc. compare | −8.15% |
| RLAY Relay Therapeutics, Inc. compare | −74.3% |
| PBLS Parabilis Medicines, Inc. compare | — |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ABCL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement